Signaling cascades in the failing heart and emerging therapeutic strategies

X He, T Du, T Long, X Liao, Y Dong… - Signal transduction and …, 2022 - nature.com
Chronic heart failure is the end stage of cardiac diseases. With a high prevalence and a high
mortality rate worldwide, chronic heart failure is one of the heaviest health-related burdens …

Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy

C Kho, A Lee, RJ Hajjar - Nature Reviews Cardiology, 2012 - nature.com
Cardiac myocyte function is dependent on the synchronized movements of Ca2+ into and
out of the cell, as well as between the cytosol and sarcoplasmic reticulum. These …

Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo …

B Greenberg, J Butler, GM Felker, P Ponikowski… - The Lancet, 2016 - thelancet.com
Summary Background Sarcoplasmic/endoplasmic reticulum Ca 2+-ATPase (SERCA2a)
activity is deficient in the failing heart. Correction of this abnormality by gene transfer might …

Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality

K Zsebo, A Yaroshinsky, JJ Rudy, K Wagner… - Circulation …, 2014 - Am Heart Assoc
Rationale: The Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In
Cardiac Disease (CUPID 1) study was a phase 1/phase 2 first-in-human clinical gene …

Dysregulation of calcium handling in duchenne muscular dystrophy-associated dilated cardiomyopathy: mechanisms and experimental therapeutic strategies

ML Law, H Cohen, AA Martin, ABB Angulski… - Journal of clinical …, 2020 - mdpi.com
Duchenne muscular dystrophy (DMD) is an X-linked recessive disease resulting in the loss
of dystrophin, a key cytoskeletal protein in the dystrophin-glycoprotein complex. Dystrophin …

AAV-mediated gene therapy: Advancing cardiovascular disease treatment

H Zhang, Q Zhan, B Huang, Y Wang… - Frontiers in …, 2022 - frontiersin.org
Gene therapy has revolutionized the field of medicine, offering new hope for those with
common and rare diseases. For nearly three decades, adeno-associated virus (AAV) has …

Potential of gene therapy as a treatment for heart failure

RJ Hajjar - The Journal of clinical investigation, 2013 - Am Soc Clin Investig
Advances in understanding the molecular basis of myocardial dysfunction, together with the
evolution of increasingly efficient gene transfer technology, make gene-based therapy a …

Rg3 promotes the SUMOylation of SERCA2a and corrects cardiac dysfunction in heart failure

Z Liu, X Bian, W Gao, J Su, C Ma, X Xiao, T Yu… - Pharmacological …, 2021 - Elsevier
SUMOylation of sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase 2a (SERCA2a) has
been shown to play a critical role in the abnormal Ca 2+ cycle of heart failure. Ginsenoside …

Cardiac gene therapy with adeno-associated virus-based vectors

K Chamberlain, JM Riyad, T Weber - Current opinion in cardiology, 2017 - journals.lww.com
Cardiac gene therapy with adeno-associated virus-based vecto... : Current Opinion in
Cardiology Cardiac gene therapy with adeno-associated virus-based vectors : Current Opinion …

A-kinase anchoring proteins in cardiac myocytes and their roles in regulating calcium cycling

H Subramanian, VO Nikolaev - Cells, 2023 - mdpi.com
The rate of calcium cycling and calcium transient amplitude are critical determinants for the
efficient contraction and relaxation of the heart. Calcium-handling proteins in the cardiac …